KRAS mutations are among the most common genetic alterations in non-small cell lung cancer (NSCLC). For many years, however, KRAS-driven cancers were considered difficult to target, with limited treatment options beyond chemotherapy and immunotherapy.
The discovery of KRAS G12C, a specific subtype of KRAS mutation, has changed this landscape. New targeted therapies are now available, offering a more personalised approach for patients with KRAS G12C lung cancer, particularly in the metastatic setting.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredWhat Is KRAS G12C Lung Cancer?
KRAS is a gene involved in regulating cell growth and signalling pathways. When mutated, it can drive uncontrolled cancer cell proliferation.
The G12C mutation refers to a specific change in the KRAS protein that locks it in an active state, continuously promoting tumour growth.
KRAS mutations are found in approximately:
- 25–30% of NSCLC cases
- KRAS G12C specifically accounts for around 10–13% of lung adenocarcinomas
This makes KRAS G12C one of the most relevant molecular subtypes in lung cancer today.
Why KRAS Was Historically Difficult to Target
Unlike other mutations such as EGFR or ALK, KRAS was long considered “undruggable”.
This is because:
- the KRAS protein has a structure that is difficult to inhibit
- it binds strongly to cellular molecules involved in signalling
- previous attempts at targeting KRAS were not clinically effective
As a result, treatment strategies historically relied on:
- chemotherapy
- immunotherapy
- supportive care
The development of KRAS G12C inhibitors represents a major breakthrough in this field.
How KRAS G12C Lung Cancer Is Diagnosed
KRAS G12C mutations cannot be identified through imaging or routine pathology alone. Molecular testing is essential.
Testing is usually performed on tumour tissue obtained through biopsy. Liquid biopsy may also be used in selected cases.
Molecular profiling allows clinicians to identify:
- KRAS mutations (including G12C)
- other actionable alterations such as EGFR, ALK or MET
- biomarkers that guide treatment decisions
Accurate molecular diagnosis ensures that patients can access appropriate targeted therapies.
KRAS G12C Targeted Therapies
Targeted therapies for KRAS G12C are designed to inhibit the mutant KRAS protein directly.
These drugs work by:
- binding to the KRAS G12C protein
- locking it in an inactive state
- preventing downstream signalling that drives tumour growth
KRAS G12C inhibitors are typically:
- used in advanced or metastatic disease
- considered after prior systemic treatment
- administered orally
These therapies have shown meaningful clinical benefit in selected patients, including improved disease control.
Treatment Strategy in Metastatic KRAS G12C Lung Cancer
Management is individualised and typically discussed in a multidisciplinary team (MDT).
Treatment options may include:
- immunotherapy
- chemotherapy
- KRAS G12C targeted therapy
- participation in clinical trials
In many cases, immunotherapy remains a key component of first-line treatment, with KRAS-targeted therapies introduced in later lines.
Resistance and Ongoing Research
As with other targeted therapies, resistance can develop over time.
Mechanisms of resistance may include:
- additional mutations in the KRAS pathway
- activation of alternative signalling pathways
- tumour heterogeneity
Research is ongoing to address these challenges through:
- next-generation KRAS inhibitors
- combination therapies
- novel treatment strategies
Side Effects of KRAS G12C Inhibitors
KRAS-targeted therapies are generally well tolerated but may cause side effects.
Common side effects include:
- fatigue
- diarrhoea
- nausea
- liver enzyme abnormalities
Most side effects are manageable with monitoring and supportive care.
The Role of Precision Oncology
KRAS G12C lung cancer represents a significant milestone in precision oncology.
After years of limited targeted options, clinicians can now offer therapies that directly target a key driver mutation.
This shift reflects a broader trend in lung cancer treatment:
- moving toward personalised medicine
- using molecular profiling to guide therapy
- improving outcomes through targeted approaches
Conclusion
KRAS G12C lung cancer is one of the most important recent advances in the treatment of non-small cell lung cancer.
Through molecular testing and the development of targeted therapies, patients with this mutation now have access to more personalised treatment options.
As research continues, KRAS-targeted therapies are expected to play an increasingly important role in lung cancer care and contribute to improving lung cancer survival rates.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Answers to common questions about KRAS G12C lung cancer, including how KRAS mutations are identified and how targeted therapies are used in modern treatment of non-small cell lung cancer (NSCLC).
KRAS G12C lung cancer is a subtype of NSCLC caused by a specific mutation in the KRAS gene.
KRAS G12C occurs in approximately 10–13% of lung adenocarcinoma cases.
Yes. Targeted therapies known as KRAS G12C inhibitors are now available for selected patients.
KRAS mutations are identified through molecular testing of tumour tissue or blood (liquid biopsy).
Yes. Resistance can develop over time, and research is ongoing to improve treatment strategies.
